Medical Device Reporting for Manufacturers; Draft Guidance for Industry and Food and Drug Administration Staff; Availability, 41069-41070 [2013-16395]
Download as PDF
Federal Register / Vol. 78, No. 131 / Tuesday, July 9, 2013 / Notices
Dated: July 2, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
you are requesting. See the
[FR Doc. 2013–16408 Filed 7–8–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–D–0743]
Medical Device Reporting for
Manufacturers; Draft Guidance for
Industry and Food and Drug
Administration Staff; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
section for
information on electronic access to the
guidance.
Submit electronic comments on the
draft guidance to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. Identify
comments with the docket number
found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Barbara Myklebust, Center for Devices
and Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 2312, Silver Spring,
MD 20993–0002, 301–796–6005.
SUPPLEMENTARY INFORMATION:
SUPPLEMENTARY INFORMATION
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of the draft guidance
entitled ‘‘Medical Device Reporting for
Manufacturers.’’ This draft guidance
describes and explains the current FDA
regulation that addresses reporting and
recordkeeping requirements applicable
to manufacturers of medical devices for
certain device-related adverse events.
This draft guidance is intended to
update FDA’s policy and to further
clarify FDA’s interpretations of the
regulation requirements and, when
final, will supersede the previous
manufacturer guidances issued in 1988
and 1997. This draft guidance also
provides answers to frequently asked
questions and includes a section on
common reporting errors. This draft
guidance is not final nor is it in effect
at this time.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by October 7,
2013.
SUMMARY:
I. Background
Submit written requests for
single copies of the draft guidance
document entitled ‘‘Medical Device
Reporting for Manufacturers’’ to the
Division of Small Manufacturers,
International and Consumer Assistance,
Center for Devices and Radiological
Health, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 66,
Rm. 4613, Silver Spring, MD 20993–
0002. Send one self-addressed adhesive
label to assist that office in processing
your request, or fax your request to 301–
847–8149. Please use the document
number 1828 to identify the guidance
The first Medical Device Reporting
(MDR) regulation became effective
December 13, 1984, with mandatory
device-related adverse event reporting
obligations for manufacturers and
importers. FDA published ‘‘Medical
Device Reporting Questions and
Answers’’ as part of its Compliance
Guidance Series in February 1988.
Subsequent changes to the reporting
requirements, including mandatory
reporting by domestic distributors and
device user facilities, resulted from
amendments to the Federal Food Drug
and Cosmetic Act (the FD&C Act) in
1990 and 1992.
The MDR regulation was revised
significantly after the 1990 and 1992
amendments to the FD&C Act. The
amended MDR regulation was
published with significant revisions on
December 11, 1995, and effective on
July 31, 1996. FDA published a
guidance document ‘‘Medical Device
Reporting for Manufacturers’’ in March
1997 to clarify the changes to reporting
requirements under the new regulation.
The FD&C Act was further modified by
amendments in 1997, 2002, and 2007,
requiring further changes to the
regulation. A plain language version of
the MDR regulation was published on
February 28, 2005, effective (in part) on
July 13, 2005.
This draft guidance describes and
explains the current FDA regulation that
addresses reporting and recordkeeping
requirements applicable to
manufacturers of medical devices for
certain device-related adverse events.
This draft guidance is intended to
update FDA’s policy and to further
clarify FDA’s interpretations of the
regulation requirements and, when
final, will supersede the previous
mstockstill on DSK4VPTVN1PROD with NOTICES
ADDRESSES:
VerDate Mar<15>2010
17:44 Jul 08, 2013
Jkt 229001
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
41069
manufacturer guidances issued in 1988
and 1997. The draft guidance also
provides answers to frequently asked
questions and includes a section on
common reporting errors.
II. Significance of Guidance
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the Agency’s current thinking
on medical device reporting for
manufacturers. It does not create or
confer any rights for or on any person
and does not operate to bind FDA or the
public. An alternative approach may be
used if such approach satisfies the
requirements of the applicable statute
and regulations.
III. Electronic Access
Persons interested in obtaining a copy
of the draft guidance may do so by using
the Internet. A search capability for all
Center for Devices and Radiological
Health guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm.
Guidance documents are also available
at https://www.regulations.gov. To
receive ‘‘Medical Device Reporting for
Manufacturers,’’ you may either send an
email request to dsmica@fda.hhs.gov to
receive an electronic copy of the
document or send a fax request to 301–
847–8149 to receive a hard copy. Please
use the document number 1828 to
identify the guidance you are
requesting.
IV. Paperwork Reduction Act of 1995
This draft guidance refers to
previously approved collections of
information found in FDA regulations.
These collections of information are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). The collection of
information in 21 CFR part 803 subparts
A to E have been approved under OMB
0910–0437 (expires August 31, 2015),
and the collection of information in 21
CFR 803.11 and 803.20 have been
approved under OMB control number
0910–0291 (expires June 30, 2015).
V. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management. It is necessary to
send only one set of comments. Identify
comments with the docket number
found in brackets in the heading of this
document. Received comments may be
E:\FR\FM\09JYN1.SGM
09JYN1
41070
Federal Register / Vol. 78, No. 131 / Tuesday, July 9, 2013 / Notices
seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday, and will be
posted to the docket at https://
www.regulations.gov.
Dated: July 1, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–16395 Filed 7–8–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Discretionary Grant Program
Health Resources and Services
Administration (HRSA), Health and
Human Services (HHS).
ACTION: Notice of Single-Source
Replacement Award to the Michigan
Public Health Institute.
AGENCY:
HRSA will be transferring the
Michigan Family-to-Family Health
Information Center (F2F HIC) grant
(H84MC09365) from the Family Center
for Children and Youth with Special
Health Care Needs (FCCYSHCN) in
Detroit, Michigan, to the Michigan
Public Health Institute (MPHI) in
Okemos, Michigan, to ensure the
continued provision of health resources,
financing, related services, and parentto-parent support for families with
children and youth with special health
care needs (CYSHCN) in the state of
Michigan.
SUMMARY:
Former
Grantee of Record: Family Center for
Children and Youth with Special Health
Care Needs.
Original Grant Period: June 1, 2008, to
May 31, 2013.
Replacement Awardee: The Michigan
Public Health Institute.
Amount of Replacement Award: Up to
$95,700 for the remainder of the project
period.
Period of Replacement Award: May 1,
2013, to May 31, 2013.
Authority: Section 501(c)(1)(A) of the
Social Security Act, as amended.
CFDA Number: 93.504.
Justification: The former grantee,
FCCYSHCN, has relinquished the F2F
HIC grant due to internal oversight
decisions. The former grantee has
requested that HRSA transfer the F2F
HIC funds to a Michigan-based family
services agency in order to implement
and carry out grant activities originally
proposed under the FCCYSHCN grant
application.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
19:11 Jul 08, 2013
Jkt 229001
The MPHI was chosen as the best
qualified grantee for this replacement
award due to its capacity to provide an
array of services to the target population
and its record of compliance and sound
fiscal management with other HHS
grants. The MPHI has demonstrated its
ability to successfully implement the
goals and objectives of the F2F HIC
project.
It is critical that the MPHI continue
helping families of CYSHCN gain access
to information they need to make
informed health care decisions, be full
partners in decision-making, and access
needed resources/referrals and
financing for those services in the state
of Michigan. It is also imperative that
the center continues to train and
support health care providers and other
professionals in public and private
agencies who serve Michigan’s
CYSHCN, helping them better
understand the needs of children,
youth, and their families.
This replacement award will ensure
that an F2F HIC will be accessible to
families and professionals to continue
providing essential information and
referral and support services to families
with CYSHCN throughout Michigan in
a manner which avoids any disruption
of services.
FOR FURTHER INFORMATION CONTACT:
LaQuanta Smalley, Integrated Services
Branch, Division of Services for
Children with Special Health Needs,
Maternal and Child Health Bureau,
Health Resources and Services
Administration, 5600 Fishers Lane,
Room 13–61, Rockville, MD 20857;
301.443.2370; lsmalley@hrsa.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
HRSA will be issuing a
grantee transfer without competition for
the Detroit Michigan Healthy Start
program to the Institute for Population
Health (IPH). The IPH will assume
responsibility for the Healthy Start
program and receive year 5 funding in
the amount of $1,575,000, from Grant
Number H49MC00147, during the
budget period of 6/1/2013–5/31/2014 to
support the objectives of the Eliminating
Disparities in Perinatal Health Healthy
Start Program.
The Eliminating Disparities in
Perinatal Health Healthy Start Program
(H49), CFDA No. 93.926, is authorized
by the Public Health Service Act, Title
III, Part D, Section 330H (42 USC 254c–
8).
The purpose of the Eliminating
Disparities in Perinatal Health Healthy
Start Program is to address significant
disparities in perinatal health.
Differences in perinatal health
indicators may occur by virtue of
education, income, disability, or living
in rural/isolated areas. To address
disparities and the factors contributing
to them, project services have been
designed to cover the pregnancy and
interconceptional phases for women
and infants residing in the proposed
project area. In order to promote longer
interconceptional periods and prevent
relapses of risk behaviors, the women
and infants are to be followed through
the infant’s second year of life and/or
two years following delivery.
SUPPLEMENTARY INFORMATION: Intended
Recipients of the Award: The Institute
for Population Health will assume
responsibilities associated with the
grant and all associated funding will be
transferred to the Institute for
Population Health.
Amount of the Non-Competitive
Award: $1,575,000
CFDA Number: 93.926
Current Project Period: 06/01/2009—
05/31/2014
Period of Grantee Transfer Funding:
6/1/2013–5/31/2014
Health Resources and Services
Administration
Authority: Public Health Service Act, Title
III, Part D, Section 330H (42 U.S.C. 254c–8).
Dated: July 2, 2013.
Mary K. Wakefield,
Administrator.
[FR Doc. 2013–16424 Filed 7–8–13; 8:45 am]
BILLING CODE 4165–15–P
Notice of Single-Case Deviation from
Competition Requirements: Transfer of
Grantee Request for the Detroit
Healthy Start Program, Detroit, MI
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice of Single-Case Deviation
from Competition Requirements:
Transfer of Grantee Request for the
Detroit Healthy Start Program, Detroit,
MI, Grant Number H49MC00147.
AGENCY:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
SUMMARY:
Justification: HRSA is transferring
responsibility of the Detroit Healthy
Start Program to the Institute for
Population Health for the purpose of
continuing Healthy Start services,
including prenatal and interconception
care, to men, women, infants, and
children residing in Wayne County. The
current grantee agency, the Detroit
Department of Health and Wellness
Promotion (DHWP) is phasing out its
provision of direct public health
services and will no longer have the
ability to manage the Healthy Start
E:\FR\FM\09JYN1.SGM
09JYN1
Agencies
[Federal Register Volume 78, Number 131 (Tuesday, July 9, 2013)]
[Notices]
[Pages 41069-41070]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-16395]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-D-0743]
Medical Device Reporting for Manufacturers; Draft Guidance for
Industry and Food and Drug Administration Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of the draft guidance entitled ``Medical Device Reporting
for Manufacturers.'' This draft guidance describes and explains the
current FDA regulation that addresses reporting and recordkeeping
requirements applicable to manufacturers of medical devices for certain
device-related adverse events. This draft guidance is intended to
update FDA's policy and to further clarify FDA's interpretations of the
regulation requirements and, when final, will supersede the previous
manufacturer guidances issued in 1988 and 1997. This draft guidance
also provides answers to frequently asked questions and includes a
section on common reporting errors. This draft guidance is not final
nor is it in effect at this time.
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency considers your comment on this
draft guidance before it begins work on the final version of the
guidance, submit either electronic or written comments on the draft
guidance by October 7, 2013.
ADDRESSES: Submit written requests for single copies of the draft
guidance document entitled ``Medical Device Reporting for
Manufacturers'' to the Division of Small Manufacturers, International
and Consumer Assistance, Center for Devices and Radiological Health,
Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm.
4613, Silver Spring, MD 20993-0002. Send one self-addressed adhesive
label to assist that office in processing your request, or fax your
request to 301-847-8149. Please use the document number 1828 to
identify the guidance you are requesting. See the SUPPLEMENTARY
INFORMATION section for information on electronic access to the
guidance.
Submit electronic comments on the draft guidance to https://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852. Identify comments with the docket number
found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Barbara Myklebust, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 2312, Silver Spring, MD 20993-0002, 301-
796-6005.
SUPPLEMENTARY INFORMATION:
I. Background
The first Medical Device Reporting (MDR) regulation became
effective December 13, 1984, with mandatory device-related adverse
event reporting obligations for manufacturers and importers. FDA
published ``Medical Device Reporting Questions and Answers'' as part of
its Compliance Guidance Series in February 1988. Subsequent changes to
the reporting requirements, including mandatory reporting by domestic
distributors and device user facilities, resulted from amendments to
the Federal Food Drug and Cosmetic Act (the FD&C Act) in 1990 and 1992.
The MDR regulation was revised significantly after the 1990 and
1992 amendments to the FD&C Act. The amended MDR regulation was
published with significant revisions on December 11, 1995, and
effective on July 31, 1996. FDA published a guidance document ``Medical
Device Reporting for Manufacturers'' in March 1997 to clarify the
changes to reporting requirements under the new regulation. The FD&C
Act was further modified by amendments in 1997, 2002, and 2007,
requiring further changes to the regulation. A plain language version
of the MDR regulation was published on February 28, 2005, effective (in
part) on July 13, 2005.
This draft guidance describes and explains the current FDA
regulation that addresses reporting and recordkeeping requirements
applicable to manufacturers of medical devices for certain device-
related adverse events. This draft guidance is intended to update FDA's
policy and to further clarify FDA's interpretations of the regulation
requirements and, when final, will supersede the previous manufacturer
guidances issued in 1988 and 1997. The draft guidance also provides
answers to frequently asked questions and includes a section on common
reporting errors.
II. Significance of Guidance
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the Agency's current thinking on medical
device reporting for manufacturers. It does not create or confer any
rights for or on any person and does not operate to bind FDA or the
public. An alternative approach may be used if such approach satisfies
the requirements of the applicable statute and regulations.
III. Electronic Access
Persons interested in obtaining a copy of the draft guidance may do
so by using the Internet. A search capability for all Center for
Devices and Radiological Health guidance documents is available at
https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance documents are also available at
https://www.regulations.gov. To receive ``Medical Device Reporting for
Manufacturers,'' you may either send an email request to
dsmica@fda.hhs.gov to receive an electronic copy of the document or
send a fax request to 301-847-8149 to receive a hard copy. Please use
the document number 1828 to identify the guidance you are requesting.
IV. Paperwork Reduction Act of 1995
This draft guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collection of information in 21 CFR part 803 subparts A to E have been
approved under OMB 0910-0437 (expires August 31, 2015), and the
collection of information in 21 CFR 803.11 and 803.20 have been
approved under OMB control number 0910-0291 (expires June 30, 2015).
V. Comments
Interested persons may submit either electronic comments regarding
this document to https://www.regulations.gov or written comments to the
Division of Dockets Management. It is necessary to send only one set of
comments. Identify comments with the docket number found in brackets in
the heading of this document. Received comments may be
[[Page 41070]]
seen in the Division of Dockets Management between 9 a.m. and 4 p.m.,
Monday through Friday, and will be posted to the docket at https://www.regulations.gov.
Dated: July 1, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-16395 Filed 7-8-13; 8:45 am]
BILLING CODE 4160-01-P